Cargando…
Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
RATIONALE: Inhaled tobramycin and oral azithromycin are common chronic therapies in people with cystic fibrosis and Pseudomonas aeruginosa airway infection. Some studies have shown that azithromycin can reduce the ability of tobramycin to kill P. aeruginosa. This trial was done to test the effects o...
Autores principales: | Nichols, David P, Singh, Pradeep K, Baines, Arthur, Caverly, Lindsay J, Chmiel, James F, GIbson, Ronald L, Lascano, Jorge, Morgan, Sarah J, Retsch-Bogart, George, Saiman, Lisa, Sadeghi, Hossein, Billings, Joanne L, Heltshe, Sonya L, Kirby, Shannon, Kong, Ada, Nick, Jerry A, Mayer-Hamblett, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043040/ https://www.ncbi.nlm.nih.gov/pubmed/34706982 http://dx.doi.org/10.1136/thoraxjnl-2021-217782 |
Ejemplares similares
-
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013) -
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022) -
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013) -
Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung
por: Tagalakis, Aristides D, et al.
Publicado: (2018) -
Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
por: Dorkin, Henry L, et al.
Publicado: (2015)